Medulloblastoma as a secondary malignancy after radiotherapy-free treatment for acute lymphoblastic leukemia

Amalia Schiavetti, Anna Clerico, Maria Debora De Pasquale, Laura Bernardini, Maria Luisa Moleti

Research output: Contribution to journalArticlepeer-review


Malignant brain tumors have been reported to occur in survivors of childhood acute lymphoblastic leukemia (ALL) more frequently than in the noncancer control population. The strongest risk factor seems to be cranial radiotherapy, used as central nervous system (CNS) prophylaxis. We report the case of a 9-year-old girl affected with metastatic medulloblastoma that developed 6 years after a diagnosis of acute lymphoblastic leukemia. CNS prophylaxis for ALL consisted of intrathecal methotrexate plus cytarabine (20 administrations) and 4 courses of high-dose methotrexate (5g/m2). No prophylactic cranial radiotherapy was administered. The child, in first complete remission, was well until the occurrence of a second tumor. She was treated for medulloblastoma with craniospinal radiotherapy and chemotherapy. At present, she is alive but with disease. As the unusual association of these 2 malignancies in this patient, the p53 status was investigated using FISH analysis by specific DNA probe; no p53 mutation was detected.

Original languageEnglish
Pages (from-to)562-564
Number of pages3
JournalJournal of Pediatric Hematology/Oncology
Issue number7
Publication statusPublished - Jul 2003


  • Children
  • Leukemia
  • Medulloblastoma
  • Second tumor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Medulloblastoma as a secondary malignancy after radiotherapy-free treatment for acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this